Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OROS Hydromorphone for Cancer Pain in Korean Patients
NCT01621100Phase 4Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2011
- Primary completion
- Sep 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hydromorphone in cancer pain, sponsored by Janssen Pharmaceutical. Primary endpoint: Pain Intensity Difference at 17 days. Started Dec 2011; status: completed.
02
Drugs
hydromorphone
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT01621100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01621100.